Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care treatment opt...

Descripción completa

Detalles Bibliográficos
Autores principales: Pauls, Mehrnoosh, Chia, Stephen, LeVasseur, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323790/
https://www.ncbi.nlm.nih.gov/pubmed/35877237
http://dx.doi.org/10.3390/curroncol29070377
_version_ 1784756640151502848
author Pauls, Mehrnoosh
Chia, Stephen
LeVasseur, Nathalie
author_facet Pauls, Mehrnoosh
Chia, Stephen
LeVasseur, Nathalie
author_sort Pauls, Mehrnoosh
collection PubMed
description Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care treatment options for metastatic TNBC, including recent advances with the use of immunotherapy, PARP inhibitors and antibody-drug conjugates. This review also explores new agents and novel combinations arising in the field for the treatment of advanced TNBC.
format Online
Article
Text
id pubmed-9323790
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93237902022-07-27 Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer Pauls, Mehrnoosh Chia, Stephen LeVasseur, Nathalie Curr Oncol Review Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care treatment options for metastatic TNBC, including recent advances with the use of immunotherapy, PARP inhibitors and antibody-drug conjugates. This review also explores new agents and novel combinations arising in the field for the treatment of advanced TNBC. MDPI 2022-07-07 /pmc/articles/PMC9323790/ /pubmed/35877237 http://dx.doi.org/10.3390/curroncol29070377 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pauls, Mehrnoosh
Chia, Stephen
LeVasseur, Nathalie
Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer
title Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer
title_full Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer
title_fullStr Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer
title_full_unstemmed Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer
title_short Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer
title_sort current and new novel combination treatments for metastatic triple-negative breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323790/
https://www.ncbi.nlm.nih.gov/pubmed/35877237
http://dx.doi.org/10.3390/curroncol29070377
work_keys_str_mv AT paulsmehrnoosh currentandnewnovelcombinationtreatmentsformetastatictriplenegativebreastcancer
AT chiastephen currentandnewnovelcombinationtreatmentsformetastatictriplenegativebreastcancer
AT levasseurnathalie currentandnewnovelcombinationtreatmentsformetastatictriplenegativebreastcancer

Ejemplares similares